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When compared to the available information for patients on dialysis (CKD stage 5D), data on the epidemiology and appropriate
treatment of calcium and phosphate metabolism in the predialysis stages of chronic kidney disease (CKD) are quite limited.
Perceptible derangements of calcium and phosphate levels start to become apparent when GFR falls below 30mL/min in some,
but not all, patients. However, hyperphosphatemia may be a signiﬁcant morbidity and mortality risk predictor in predialysis
CKD stages. The RIND study, evaluating progression of coronary artery calciﬁcation in incident hemodialysis patients, indirectly
demonstratedthatvascularcalciﬁcationprocessesstarttomanifestinCKDpatientspriorto thedialysisstage,whichmaybeclosely
linked to early and invisible derangements in calcium and phosphate homeostasis. Novel insights into the pathophysiology of
calciumandphosphate handling such as the discovery of FGF23 andother phosphatoninssuggest that a more complex assessment
ofphosphate balance is warranted, possiblyincluding measurements of fractionalphosphate excretion and phosphatoninlevels in
order to appropriately evaluate disordered metabolism in earlier stages of kidney disease. As a consequence, early and preventive
treatment approaches may have to be developed for patients in CKD stages 3-5 to halt progression of CKD-MBD.
1.Introduction
Availability of phosphate is of key importance for a number
of normal physiological body functions including bone de-
velopment, cellular membrane integrity (phospholipid con-
tent), and energy transfer (mitochondrial metabolism).
Normal phosphate homeostasis, thus, maintains serum con-
centrations quite constantly between 0.8 and 1.45mmol/L in
the normal population. In this line, meals containing a high
phosphate load in most instances do not acutely raise the
serum phosphate levels, because phosphaturia may become
augmented by as yet undeﬁned mechanisms [1]. Further-
more, serum phosphate levels show rather a circadian
rhythm which does not parallel intake (phosphate peaks in
the early morning hours) [2]. In health, the kidney excretes
approximately two thirds of the daily dietary phosphate
load, and even with deteriorating kidney function in CKD,
this excretion rate remains relatively well maintained [3].
Acute “unphysiological” oral phosphate intake is probably
managed by the so-called phosphatonins or by adaptations
of the ﬁltered load [3, 4]. It appears that the body activates
a number of potent systems in order to avoid both the
occurrence of hyperphosphatemia.
2.Epidemiologyof Hyperphosphatemiain
CKDPatients
Kestenbaum and colleagues were the ﬁrst to publish data
from a large observational study studying the relationship
between phosphate serum levels and outcomes in a CKD
cohort [5]. More than 6,000CKD patients were cross-
sectionally available for analysis, while 3,490 of them had a
serumphosphate measurement during thepreviouseighteen
months. The major result was that phosphate serum levels
were found to be in the normal range until a GFR of
30mL/min was reached; only from then on average phos-
phate levels started to rise beyond the upper normal range
and started to become inversely related to GFR, while it
is yet unclear when serum phosphate levels tend to rise
“within” the normal range in CKD [6]. In Kestenbaum’s
study, serum phosphate levels above 3.5mg/dL were already2 International Journal of Nephrology
signiﬁcantly associated with mortality. Further, mortality
risk progressively increased with each 0.5-mg/dL increase in
phosphate serum levels. In a prospective, community-based,
noninterventional, prospective cohort study (SEEK study,
n = 1814CKD patients), Levin and colleagues were able to
demonstrate similar ﬁndings with regard to the incidence of
“visible” hyperphosphatemia—phosphate serum levels rose
perceptibly in subjects in CKD stage 4 [7]. Therefore, both
studies support the assumption that hyperphosphatemia
mayjustbetheﬁnalindicator(tipofaniceberg)ofanalready
previously failing phosphate balance.
3.Phosphate Homeostasisin CKD
Up to 80% of the estimated daily phosphate intake of
20mg/kg b.w. per day is intestinally absorbed in healthy
individuals and circulates into an “extracellular phosphate
pool” [3]. 3mg/kg b.w. phosphate per day are exchanged
between this virtual pool and the bone, if bone turnover is
physiologically balanced. Two-thirds of the daily intake is
excreted via healthy kidneys, the other third is excreted by
the faeces resulting in a neutral phosphate balance. Kidney
disease interferes with the ability to excrete phosphate loads;
however, excretion remains surprisingly stable until the late
stages of CKD.
The fact that there is a delayed onset of hyperphos-
phatemicepisodesinCKDisprobablybasedoncounterregu-
latory actions ofFGF23 and PTH [8–11].Bothhormones are
causing phosphaturia when elevated and apparently become
stimulatedas earlyasinCKDstage3,connectedtovitamin D
status and dietary phosphate intake. Both in animal models
as well as in human studies, it was shown that increases in
serumFGF23levelswereparalleledbyrisesinrenalfractional
(relative) phosphate excretion counteracting increases in
phosphateretentionandsubsequenthyperphosphatemia[8–
11]. It is currently considered that a positive phosphate
balance triggers an osteocyte “phosphate sensor” towards
signalling releaseofFGF23.Inthiscontext,itisyetunknown,
whether phosphate itself is the circulating messenger, or
whether for example intestinal phosphatonins may serve
as FGF23 inducers [3]. Furthermore, FGF23 and PTH
secretion may be linked to each other. FGF23 actively sup-
presses calcitriol synthesis, thus antagonizing a central PTH-
suppressive mechanism [9, 10]. Therefore, the organism
employs two diﬀerent hormonal systems in order to shelter
the body from phosphate accumulation, that is, hyperphos-
phatemia. There are also data that PTH and FGF23 secretion
are directly interconnected, that is, that FGF23 inhibits PTH
release via stimulating the dimeric klotho/FGF-receptor at
the parathyroid gland [12]. PTH may vice versa inhibit
FGF23 release from the osteocyte [12].
With this in mind, the question arises how acute dietary
phosphate ingestion may inﬂuence phosphate, FGF23, and
PTH regulation in CKD? Isakova et al. studied a group of
CKD patients (GFR 20–45ml/min) versus healthy individ-
uals ingesting a meal with a phosphate content of 500mg
of phosphate [1]. Within 4 hours following ingestion, they
found no increase in serum phosphate levels in both groups,
but a rapid augmentation of fractional phosphate excretion
in the healthy control group, while the baseline level of uri-
nary excretion was already twice as high in the CKD cohort,
with a nonsigniﬁcant trend towards a further increase. This
phosphaturic response was not acutely accompanied by
increases in FGF23 or PTH levels, while at baseline these
two parameters were also already signiﬁcantly elevated in
the CKD group versus the healthy controls. This study had
a few limitations including the fact that the exact timing of
interventions was not presented. Nevertheless, this response
excludes FGF23 as the predominant “acute-phase” phospha-
tonin regulating phosphate excretion, but FGF23 may work
as a “memory hormone” and a long-term regulator of a
positive phosphate balance. This behaviour may be more
comparable to the marker protein of diabetes control,
HbA1C, with the additional property that FGF23 not just
represents, but also acts on phosphate control. Thus, these
insights suggest the existence of additional acute regulatory
factors of phosphate balance which remain to be identiﬁed
in the future.
4.TreatmentofPhosphate Retentionin
PredialysisCKD:Diets
Therapeutic approaches aiming at phosphate lowering (i.e.,
serum levels as well as phosphate load) include reducing
oral intake of phosphate by dietary modiﬁcations as well as
intestinal absorption using phosphate binders. Phosphate-
restricted diets should be designed in a manner that avoids
simultaneous protein malnutrition. In this context, there
are a couple of studies supporting that at least moderate
phosphate restriction is well tolerated in most individuals.
The use of phosphate-restricted diets in combination with
oral phosphate binders has become well established in
the management of patients with CKD Stages 3–5CKD
(including CKD Stage 5D). Recent epidemiological studies
in larger cohorts of dialysis patients are uniequivocal regard-
ing associations between dietary phosphate restriction and
survival beneﬁts [13, 14].
Two prospective studies are available speciﬁcally evaluat-
ing theimpactofphosphate-restricted dietsinCKDpatients.
Zelleretal.showed thattherestrictionofdietaryproteinplus
phosphate intake was welltolerated and maintained nutri-
tional parameters in a satisfying range in a study of 35 Type
I diabetes patients with associated nephropathy [15]. Here, a
signiﬁcant reduction in urinary phosphate excretion in the
group assigned to a protein/phosphate restriction as com-
pared to subjects receiving a control diet was found. There
was no evaluation of other CKD-MBD-related parameters
performedinthisinvestigation.Lafage-Proustandcolleagues
reported in another study featuring a very strict low-protein,
low-phosphorus diet (supplemented with essential amino
acids and their ketoanalogs) that after a follow-up of ﬁve
years bone formation rate was normal or high in 10 patients,
and low in the remaining 6, without observing low-protein-
associated malnutrition in any of the participants [16].
A new view on phosphate restriction currently develops
based on considerations that there might be a signiﬁcant
diﬀerence between naturally occuring phosphate and phos-
phate supplements in food [17–19]. Natural phosphate isInternational Journal of Nephrology 3
Table 1:KDIGO clinicalpractice guideline for the diagnosis,evaluation,prevention,and treatment ofChronicKidney Disease-Mineraland
Bone Disorder (CKD-MBD) [14]: recommendations for the management of phosphate in predialysis patients.
(4.1.1) In patients with CKD stages 3–5, we suggest maintainingserum phosphorus in the normalrange (2C).
(4.1.4)
In patients with CKD stages 3–5 (2D) and 5D (2B), we suggest using phosphate binding agents in the treatment of
hyperphosphatemia. It is reasonable that the choice of phosphate binder takes into account CKD stage, presence of other
components of CKD-MBD, concomitanttherapies, and side eﬀect proﬁle (not graded).
(4.1.5) In patients with CKD stage 3–5D and hyperphosphatemia, we recommend restricting the dose of calcium-based phosphate
binder and/or the dose of calcitriol or vitamin D analog in the presence of persistent or recurrent hypercalcemia (1B).
In patients with CKD stage 3–5D and hyperphosphatemia, we suggest restricting the dose of calcium-based phosphate binders in
the presence of arterial calciﬁcation (2C) and/or adynamic bone disease (2C) and/or if serum PTH levels are persistently low (2C).
(4.1.6) In patients with CKD stage 3–5D we recommend avoiding long term use of aluminum containing phosphate binders and in
patients with CKD stage 5D avoiding dialysate aluminum contaminationto prevent aluminum intoxication (1C).
(4.1.7) In patients with CKD stages 3–5D, we suggest limiting dietary phosphate intake in the treatment of hyperphosphatemia alone or
in combination with other treatments (2D).
mostly contained in food as organic esters or as phytates
(hexa-phospho-inosites), and this bound phosphate is only
absorbed at a rate between 40–60% at maximum [20–22].
In contrast, phosphate-containing food additives include
polyphosphates, diphosphates, triphosphates, potassium
phosphate, calcium phosphate and so on, while this “free”
phosphate is quite readily absorbed [19]. Recently, it became
evident from longitudinal observations of the “Chronic
Renal Insuﬃciency Cohort” (CRIC) cohort that patients
with mild to moderate renal insuﬃciency had a 2.5–2.7-fold
increasedriskofhyperphosphatemia (>4,6mg/dL)when the
tlowest income tertile was compared to the highest income
tertile, despite equal amounts of phosphate intake (1,156
versus 1,190mg/Tag) [23]. This diﬀerence could only be
explained by diﬀerencesin “phosphatequality,”with ahigher
intake of the so-called “fast food” (which is particularly rich
in phosphate additives) in the lower income group.
5.Treatmentof Phosphate Retentionin
PredialysisCKD:PhosphateBinders
Phosphate binders are pragmatically used in predialysis
patients when hyperphosphatemia becomes apparent how-
ever, thresholds for treatment initiation vary a lot and are
mostly based on preferences at the discretion of the indi-
vidual physician. The KDIGO guidelines 2009 (Table 1)
suggest to maintain phosphate serum levels within the
normal range in CKD patients in stages 3–5 [24], but
mild hyperphosphatemia can still be considered an under-
recognized and underestimated phenomenon in predialysis
patients. Calcium-containing binders may globally play a
predominant role as the ﬁrst-line choice ofphosphate binder
therapy in these predialysis stages, because they are relatively
inexpensive and because these patients tend to have calcium
s e r u ml e v e l si nt h el o w e ro re v e nb e l o wt h en o r m a lr a n g e .
Since many CKD patients suﬀer from a low mineral den-
sity, there is also the question, whether a negative calcium
b a l a n c em u s tb ea v o i d e da n y w a y ,b u tt h e r ei sn oa n s w e ro n
theharmless orevenbeneﬁcialcalciumintakequantitiesthat
can be permitted. However, we also know quite well that
increased calcium exposure, or a positive net calcium bal-
ance, maypredispose CKDpatientsfortherisk ofdeveloping
cardiovascular calciﬁcation [25, 26].
Ofnote,withtheexceptionofcalciumcarbonateinmany
European countries, phosphate binder treatment had gener-
ally been an oﬀ-label use in these CKD stages tolerated by
most authorities until recently. In 2009, however, sevelamer
carbonate was approved by the EMA in the indication of
treating CKD patients not on dialysis with phosphate serum
levels of above 1.78mmol/L in Europe. The same label was
also approved for lanthanum carbonate a few months later.
There are only few publications available on phosphate
binder use in predialysis patients. Such studies are furthers
hampered by the fact that phosphate-lowering eﬀects are not
clearly visible, because a decline in phosphaturia may blunt
the changes in circulating phosphate levels.
The eﬃcacy of sevelamer carbonate in predialysis CKD
patients was recently examined in 19 nephrology centers
across Northern Europe and Australia in a single-arm study
approachwithapoststudywashoutperiod[27].Investigators
initially screened 129 patients, 41 of whom completed the
study. Recruitment was heavily inﬂuenced by screening
failure, because the cutoﬀ of phosphate serum levels was set
very high (5.5mg/dL), according to authority requirements
in the study protocol, which also caused a high inclusion
percentage of patients in CKD stage 5. Sevelamer carbonate
lowered serum phosphorus levels by a mean of 1.4 ± SD
1.0mg/dL (P<. 001) during an eight-week observation
period. 70% of those patients with stage 4CKD achieved
normal serum levels of 2.7–4.6mg/dL. Serum bicarbonate
concentrations rose signiﬁcantly from 16.6 ± 3.6mEq/Lto
18.2 ± 3.7mEq/L (P = .005) which may be clinically
meaningful given the high prevalence of metabolic acidosis
in CKD stage 4-5 patients. The mean prescribed dosage after
dosage titration was 7.8g/daysevelamer carbonate at the end
of the study.
Lanthanum carbonate was also studied recently in a
Phase II trial in CKD stage 3 and 4 patients [28]. 121 hyper-
phosphatemic patients were randomized in a 2:1 manner
to lanthanum or placebo, respectively. 44.6% of lanthanum-
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in the placebo group, with safety proﬁle and tolerability on
a strictly comparable level. The mean dose of lanthanum
carbonate after eight weeks was 2,645 ± 97mg/day.
The RIND study provided some more indirect insights
into the clinical potential of phosphate binder treatment in
p r e d i a l y s i ss t a g e s[ 25]. This investigation was designed as a
prospectivetrialobservingtheprogressionofcoronaryartery
calciﬁcations in incident hemodialysis patients treated with
either sevelamer-HCl or calcium acetate. One central obser-
vation was that even though none of the patients who were
free of calciﬁcations became positive during the ﬁrst 18
months of dialysis treatment, “progressors” (about 60% of
the total cohort) were all calciﬁed prior to initiation of dial-
ysis treatment. Thus, prevention strategies targeting car-
diovascular calciﬁcation, such as phosphate-lowering app-
roaches, must be initiated early in the course of CKD.
Currently, there is only one prospective clinical study
addressing the biological eﬀect of phosphate binders in
CKD patients [29]. Russo and colleagues studied 90 phos-
phate binder-naive patients in predialysis CKD stages 3–5
with regard to progression of coronary artery calciﬁcation.
Patients were randomized (30 per group) to either a low P
diet alone, or to a low P diet in combination with ﬁxed doses
ofcalciumcarbonate(2g/day)orsevelamer(1.6g/day).Final
MSCT-basedcoronaryarterycalciﬁcationscoresweregreater
than initial scores in those subjects receiving diet and diet in
combination with calcium carbonate, while no progression
was observed in the diet plus sevelamer-treated group.
Absolute urinary phosphate excretion was higher in the diet-
treated patients but lower when compared to baseline in
those receiving phosphate binders. FGF23 serum levels were
unfortunately not available from this study.
6.Novel ConceptsforPhosphate Management
inPredialysisCKDStages
One of the key issues in phosphate management in predial-
ysis stages of CKD is the fact that serum phosphate levels
do not appropriately reﬂect phosphate retention. Because
phosphate retention is immediately counterregulated by
phosphatonins such as FGF23, PTH, and probably other
factors, composite measurements of these parameters may
need to ﬁnd their way into diagnostic algorithms, as well
as estimates of phosphate excretion in the urine. Nagano
et al. recently demonstrated in a uremic rat model that
phosphate binding by sevelamer dose-dependently lowered
both FGF23 and PTH serum concentrations [30]. In this
line, two clinical pilot studies were launched investigating
the eﬀect of phosphate binder treatment on these surrogate
parameters of phosphate retention. Isakova et al. studied 16
normophosphatemic CKD stage 3 and 4 patients to either
lanthanum carbonate or placebo, and to either a 750mg
or 1,500mg phosphate diet, in a 2 × 2 factorial design
[31]. FGF23, PTH, serum levels of calcium and phosphate,
and phosphate excretion were measured. While the high
phosphate diet and lanthanum treatment lead to decreases
in phosphate excretion, no eﬀects were observed with regard
to FGF23 and PTH levels, respectively. However, the high
phosphate diet caused a signiﬁcant increase in FGF23 levels.
Block and colleagues started a similar, but larger pilot
study in >200 normophosphatemic CKD patients (eGFR
20–45ml/min) using three diﬀerent phosphate binders (lan-
thanum carbonate, sevelamer carbonate, calcium acetate)
withmatchingplacebos[32].Follow-upwill beninemonths,
and parameters of interest are serum concentrations of
FGF23, PTH, calcium, and phosphate, as well as changes in
arterial stiﬀness (pulse wave velocity) and coronary artery
celaciﬁcation scores (multislice spiral CT). Data are expected
to be available in autumn 2011.
The biologically plausible hypothesis that “invisible”
phosphate retention may be the earliest and foremost event
in the development of secondary hyperparathyroidism was
already picked up in concept papers [33]. Here, a “phos-
phocentric” (in contrast a “vitamin D-centric”) view was
proposed with the consequence that the initial treatment
approach must be targeted towards limiting phosphate
ingestion and absorption in predialysis patients. This view
wasrecentlysupportedbyEvenepoeletal.whodemonstrated
that urinary phosphate excretion in predialysis CKDpatients
was indeed highest in individuals with both elevated FGF23
and PTH, respectively, and that increased FGF23 and phos-
phate, and decreased 25-OH-vitamin D were independently
associated with decreased calcitriol levels [34]. What needs
to be determined and better understood though is, whether,
or to which degree, secondary hyperparathyroidism (and
FGF23 elevations) is a favourable, adaptive or a disadvan-
tageous, maladaptive mechanism, prior to basing treatment
decisions on this novel concept. Furthermore, age, klotho
expression, andpotentiallyklothoresistance(inuremia) may
impact on shifting phosphate regulation to dysregulation
[3, 9, 10, 12].
7.Conclusion
Much needs to be learned about the assessment and the
impact of deranged phosphate homeostasis in predialysis
CKD stages. Limited data suggest that phosphate retention
may cause harm in these stages even if serum levels do not
rise beyondthe normal range. Composite measures ofserum
phosphate, fractional phosphate excretion, and FGF23 may
become an integral and improved approach in therapeutic
decision making, in contrast to just waiting for hyperphos-
phatemia to occur. However, there is a huge gap with regard
to prospective clinicaltrials assessing the eﬀectof phosphate-
lowering strategies on clinically meaningful hard endpoints.
In addition, since a positive phosphate balance may already
tip the balance towards cardiovascular calciﬁcation and
damage, we require information on the impact of treatment
on cardiovascular surrogate parameters as well. Fortunately,
there are initiatives underway attempting to at least partially
ﬁll those gaps of knowledge.
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